Delcath Systems, Inc.DCTH

Delcath Systems Inc. is a micro-cap oncology outfit chasing a single asset: the Delcath System, a proprietary second-generation (GEN2) hemofiltration platform designed to isolate and filter high-dose melphalan directly in the liver during percutaneous hepatic perfusion procedures. The company’s clinical-trials rail lists active investigator-initiated studies across leading US and European cancer centres, while its news page doles out the occasional update on conference abstracts and case series. What the platform promises, in short, is a shot at improving outcomes in metastatic ocular or intrahepatic cholangiocarcinoma-markets so small that even a single Phase II success could shift the stock’s narrative overnight.

The promise is real, yet the income statement is not. For the quarter ended 31 March 2026, Delcath banked $25 million of revenue, booked a net loss of $1.1 million, and posted positive-but thin-operating cash flow of $857 thousand. The balance sheet, though, still looks sturdy: $124.8 million in assets against $12.1 million in liabilities, with $41.3 million in cash and equivalents and $112.7 million in shareholders’ equity. In other words, the company can keep the lights on and fund its current R&D pipeline, but it is not yet self-funding the next leg of commercial scale-up.

The numbers are drawn straight from the freshly filed 10-Q. Revenue of $25.0 million came from customer contracts, operating loss of $1.6 million and net loss of $1.1 million were posted, and R&D spend clocked in at $9.8 million. Inventory sat at $9.8 million net, down $444 thousand from the prior quarter, while capitalised capex for the period was $570 thousand. The company’s weighted average diluted share count rose to 36.0 million, translating to an EPS loss of $0.03. (source: 10-Q for the period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/872912/000119312526222899/d94596d8k.htm)

Anyone hunting for a chart can pull the daily line on OTCQB under ticker DCTH via their broker’s feed; TradingView’s public route is https://www.tradingview.com/chart/?symbol=OTCQB:DCTH. The security is thinly traded, so the quote tends to wander rather than march, and the spread can yawn wider than the company’s current R&D budget when liquidity dries up. In short, if you’re not trading around a clinical read-out or an FDA nod, the stock is more curiosity than conviction vehicle.

The operating narrative remains tethered to the GEN2 platform’s clinical progress. Delcath’s official rails list ongoing trials, including a prospective evaluation of the GEN2 system in patients undergoing percutaneous hepatic perfusion with melphalan, alongside a rolling library of peer-reviewed publications and investigator-initiated research proposals. The company also hosts a ‘Research & Educational Support’ portal inviting non-promotional, investigator-led studies that align with its therapeutic focus. These are real scientific endeavours, yet none has yet crossed the finish line that turns red ink into black. (source: Clinical Trials rail, https://delcath.com/our-therapy/clinical-trials_x/; Research & Educational Support rail, https://delcath.com/research-educational-support/)